logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

HAIER SMARTHOME (06690) completes the issuance of 1.5 billion yuan of green two new medium-term notes.

date
21:13 06/03/2025
avatar
GMT Eight
Haier Smart Home (06690) announced that the company has recently completed the first phase of green bonds for 2025.
HAIER SMARTHOME (06690) announced that the company has recently completed the issuance of the first phase of green bonds for 2025, with a total issuance amount of 1.5 billion RMB, a coupon rate of 1.99%, and a maturity period of 3 years.
Related Articles
HK Stock
LYUE PHARMA (02186) innovative drug LY03015 (VMAT2 inhibitor/Sigma-1R agonist) has achieved positive results in the Phase II clinical trial for the treatment of delayed onset movement disorders in China.
HK Stock
IMMUNEONCO-B (01541) spent HK$592,500 to repurchase 163,200 shares on June 16.
China Stock
Hubei Heyuan Gas Co., Ltd. (002971.SZ): Qian Tu privately reduces holdings to below 5%, planning to continue reducing holdings by no more than 1% of the shares.
LYUE PHARMA (02186) innovative drug LY03015 (VMAT2 inhibitor/Sigma-1R agonist) has achieved positive results in the Phase II clinical trial for the treatment of delayed onset movement disorders in China.
HK Stock
IMMUNEONCO-B (01541) spent HK$592,500 to repurchase 163,200 shares on June 16.
HK Stock
Hubei Heyuan Gas Co., Ltd. (002971.SZ): Qian Tu privately reduces holdings to below 5%, planning to continue reducing holdings by no more than 1% of the shares.
China Stock
RECOMMEND
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
icon
10/06/2026
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
icon
10/06/2026
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
icon
10/06/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.